THDB(SH:600867)2020-08-19 16:00Financial Performance - The company's operating revenue for the first half of 2020 was CNY 1,474,803,815.08, representing a 2.80% increase compared to CNY 1,434,663,884.88 in the same period last year[14]. - The net profit attributable to shareholders was CNY 541,359,485.77, which is a 1.73% increase from CNY 532,144,473.71 year-on-year[14]. - The net cash flow from operating activities reached CNY 599,283,637.94, up by 3.71% from CNY 577,830,029.31 in the previous year[14]. - The total profit for the same period was CNY 635.57 million, up by 2.76% year-on-year, while the net profit attributable to shareholders was CNY 541.36 million, reflecting a 1.73% increase[22]. - The company reported a total comprehensive income of CNY 540,524,651.76 for the first half of 2020, compared to CNY 530,655,630.89 in the same period of 2019, indicating a growth of about 1.6%[99]. - The basic earnings per share for the first half of 2020 was CNY 0.27, which is a 3.85% increase compared to CNY 0.26 in the same period last year[14]. - The total operating profit for the first half of 2020 was CNY 642,427,078.91, up from CNY 597,258,994.51 in the previous year[100]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,675,912,589.03, reflecting a 6.09% increase from CNY 5,349,909,572.36 at the end of the previous year[14]. - The total liabilities increased to CNY 597,193,377.64 from CNY 341,098,913.76, reflecting a growth of about 75.3%[93]. - The total equity attributable to shareholders increased to CNY 5,071,138,289.30 from CNY 5,000,394,902.50, showing a growth of approximately 1.4%[93]. - Current liabilities rose to CNY 558,077,144.67, compared to CNY 304,847,302.44, indicating an increase of approximately 82.8%[92]. - The company's retained earnings rose to CNY 1,668,893,006.79 from CNY 1,531,111,224.42, representing an increase of approximately 9.0%[93]. Research and Development - Research and development expenses increased by 46.16% to ¥51,642,892.66, reflecting the initiation of new R&D projects[47]. - The company is advancing the research and development of degludec insulin and semaglutide to expand its product pipeline in the diabetes treatment field[24]. - The company has a strong focus on innovation, with multiple awards for its research and development efforts in insulin production[20]. - The company has initiated the development of Somaglutide, a long-acting GLP-1 receptor agonist, with preliminary process development completed and key parameter screening ongoing[36]. Market Position and Products - The company has a market share of over 25% for its recombinant human insulin injection (brand name: Gan Shulin), ranking second in the market[19]. - The company has launched its long-acting insulin injection (brand name: Chang Shulin), becoming the third company in China to do so, which is expected to strengthen its market position[19]. - The company is actively expanding its product line, including second and third-generation insulin products, with plans for future fourth-generation insulin[19]. - The company’s recombinant human insulin production technology is at an advanced level, with the largest fermentation system among domestic producers[20]. Corporate Governance and Compliance - The company reported no significant risks that could materially affect its operations during the reporting period[4]. - The company has no major litigation or arbitration matters during the reporting period[68]. - The company has not changed its accounting firm during the reporting period, continuing with Zhongjun Accounting Firm for the 2020 financial report audit[66]. - The company has completed the application for the pollutant discharge permit by June 20, 2020, and is currently under review[72]. Environmental and Social Responsibility - The company is actively investing in environmental protection efforts to become a resource-saving and environmentally friendly enterprise[78]. - The company has installed an online monitoring system for wastewater and emissions, which is connected to the environmental protection department's platform for continuous compliance[72]. - The average concentration of COD in wastewater discharge was 12.66 mg/L, well below the permitted concentration of 80 mg/L[73]. - The company has developed emergency response plans for sudden environmental incidents, which have been approved and filed with relevant authorities[77]. Shareholder Information - The largest shareholder, Dongbao Industrial Group Co., Ltd., holds 774,758,354 shares, accounting for 38.09% of total shares[81]. - The company has a total of CNY 616,816,520.81 in surplus reserves at the end of the reporting period[120]. - The company has undergone multiple increases in share capital through stock bonuses and private placements, reflecting a strategy of enhancing shareholder value and expanding its capital base[161]. - The company has a history of consistent profit distribution, with cash dividends and stock bonuses being issued to shareholders over the years[127].